NASDAQ:ISPC iSpecimen (ISPC) Stock Price, News & Analysis $0.58 -0.02 (-3.29%) As of 11:00 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsNews and TrendsOwnershipSEC Filings About iSpecimen Stock (NASDAQ:ISPC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get iSpecimen alerts:Sign Up Key Stats Today's Range$0.58▼$0.6050-Day Range$0.60▼$1.5952-Week Range$0.57▼$27.44Volume7,514 shsAverage Volume520,678 shsMarket Capitalization$1.47 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview iSpecimen, Inc. operates an online marketplace that connects life-science researchers with hospitals, laboratories, biobanks and other providers of human biospecimens. Its platform is designed to help researchers find and request samples for medical and scientific research. Through its iSpecimen Marketplace, the company facilitates access to materials such as blood, tissue and other human specimens, along with associated data when available. It also supports the coordination of specimen sourcing and fulfillment between research organizations and providers. Founded in 2009 by Christopher Ianelli, iSpecimen has built a network intended to serve research organizations and specimen providers in the United States and internationally.AI Generated. May Contain Errors. Read More iSpecimen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks9th Percentile Overall ScoreISPC MarketRank™: 0.42558850911 of 5 starsiSpecimen scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingiSpecimen has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageiSpecimen has only been the subject of 1 research reports in the past 90 days.Read more about iSpecimen's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of iSpecimen is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of iSpecimen is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioiSpecimen has a P/B Ratio of 0.04. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.80% of the float of iSpecimen has been sold short.Short Interest Ratio / Days to CoveriSpecimen has a short interest ratio ("days to cover") of 0.74, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in iSpecimen has recently increased by 92.25%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldiSpecimen does not currently pay a dividend.Dividend GrowthiSpecimen does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.39 News SentimentiSpecimen has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for iSpecimen this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for ISPC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added iSpecimen to their MarketBeat watchlist in the last 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, iSpecimen insiders have not sold or bought any company stock.Percentage Held by Insiders12.20% of the stock of iSpecimen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions13.62% of the stock of iSpecimen is held by institutions.Read more about iSpecimen's insider trading history. Receive ISPC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iSpecimen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ISPC Stock News HeadlinesiSpecimen Reports Delay in Its Quarterly Filing3 hours ago | tipranks.comiSpecimen (NASDAQ:ISPC) Stock Jumps 0.8% - Time to Buy?November 7, 2026 | americanbankingnews.comYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on Elon Musk's next big industry play. He estimates it could create 1.8 million new millionaires in the coming years, and shows how to position in the company at its center for under $60. Inside: the company's name and ticker, plus an FCC filing James believes reveals Elon's plan to take over a $25 trillion industry. He also flags December 8 as a key date.November 17 at 1:00 AM | Paradigm Press (Ad)iSpecimen Shareholders Approve Key Financing and Acquisition ActionsOctober 9, 2026 | tipranks.comISpecimen In Focus, Genelux Nears Phase 3 Ovarian Cancer Data, Biofrontera Awaits FDA DecisionSeptember 8, 2026 | rttnews.comiSpecimen to Acquire Foldlab AI Disease AnalyticsSeptember 4, 2026 | tipranks.comiSpecimen Completes Large-Scale International Cancer Research Order; Samples Shipped Within Three WeeksAugust 20, 2026 | globenewswire.comiSpecimen Engages IR Agency for Investor MarketingAugust 14, 2026 | tipranks.comSee More Headlines ISPC Stock Analysis - Frequently Asked Questions How have ISPC shares performed this year? iSpecimen's stock was trading at $10.4040 at the start of the year. Since then, ISPC stock has decreased by 94.2% and is now trading at $0.6049. How were iSpecimen's earnings last quarter? iSpecimen Inc. (NASDAQ:ISPC) issued its quarterly earnings data on Tuesday, November, 17th. The company reported ($1.03) EPS for the quarter. The company earned $244.03 thousand during the quarter. iSpecimen had a negative trailing twelve-month return on equity of 524.39% and a negative net margin of 2,445.40%. When did iSpecimen's stock split? iSpecimen shares reverse split before market open on Tuesday, April 28th 2026.A 1-40 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 27th 2026. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did iSpecimen IPO? iSpecimen (ISPC) raised $20 million in an initial public offering on Tuesday, June 15th 2021. The company issued 2,250,000 shares at $8.00-$10.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO. How do I buy shares of iSpecimen? Shares of ISPC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of iSpecimen own? Based on aggregate information from My MarketBeat watchlists, some other companies that iSpecimen investors own include Advanced Micro Devices (AMD), NIO (NIO), Biofrontera (BFRI), NVIDIA (NVDA), Palantir Technologies (PLTR), Longeveron (LGVN) and AST SpaceMobile (ASTS). Company Calendar Last Earnings8/14/2026Today11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (10m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ISPC's financial health is in the Red zone, according to TradeSmith. ISPC has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:ISPC CIK1558569 Webispecimen.com Phone781-301-6700FaxN/AEmployees7Year FoundedN/AProfitability EPS (Trailing Twelve Months)($56.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.49 million Net Margins-2,445.40% Pretax Margin-2,445.61% Return on Equity-524.39% Return on Assets-140.42% Debt Debt-to-Equity RatioN/A Current Ratio0.82 Quick Ratio0.82 Sales & Book Value Annual Sales$1.93 million Price / Sales0.76 Cash FlowN/A Price / Cash FlowN/A Book Value$14.57 per share Price / Book0.04Miscellaneous Outstanding Shares2,520,000Free Float2,212,000Market Cap$1.47 million OptionableNot Optionable Beta1.54 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:ISPC) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full ...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredThe $40 trillion number nobody won on Tuesday will touchDemocrats took the House and Senate on election night, but the $40 trillion national debt and the $1 trillion ...Vault Metal | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iSpecimen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iSpecimen With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.